Results 31 to 40 of about 347,254 (297)

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age

Human Vaccines & Immunotherapeutics, 2022
Vaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines in incidence ...
Gary S. Marshall, Stephen I. Pelton, Corwin A. Robertson, Philipp Oster   +3 more
doaj   +1 more source

Conjugate vaccines

Expert Review of Vaccines, 2003
Conjugate vaccines in which the capsular polysaccharide of Haemophilus influenzae type b, common serotypes of Streptococcus pneumoniae and group C Neisseria meningitidis are covalently bound to a protein antigen to convert a T-cell-independent immune response into a T-cell-dependent response have proved highly effective in the prevention of invasive ...
openaire   +2 more sources

Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009

Journal of Infection in Developing Countries, 2010
Enteric fever is responsible for significant morbidity in South Asia and high prevalence of severe disease is seen in children under two years of age. Effective typhoid vaccines are available, but they cannot be used for children under two years of age
Audino Podda, Allan James Saul, Rashmi Arora, Zulfiqar Bhutta, Anju Sinha, Rajni Gaind, Tanu Singhal, Samir Saha, Abdullah Brooks, Laura B. Martin, Yeshwant Amdekar, Amar Jeet Chitkara, Mae Shieh, Ambujam Nair Kapur, Tulsi Das Chugh   +14 more
doaj   +1 more source

Production of glycoprotein vaccines in Escherichia coli

Microbial Cell Factories, 2010
Background Conjugate vaccines in which polysaccharide antigens are covalently linked to carrier proteins belong to the most effective and safest vaccines against bacterial pathogens.
Ihssen Julian, Kowarik Michael, Dilettoso Sandro, Tanner Cyril, Wacker Michael, Thöny-Meyer Linda   +5 more
doaj   +1 more source

Glycolipid‐peptide conjugate vaccines elicit CD8+ T‐cell responses and prevent breast cancer metastasis

Clinical & Translational Immunology, 2022
Objectives Metastasis is the principal cause of breast cancer mortality. Vaccines targeting breast cancer antigens have yet to demonstrate clinical efficacy, and there remains an unmet need for safe and effective treatment to reduce the risk of ...
Olivia K Burn, Kathryn Farrand, Tara Pritchard, Sarah Draper, Ching‐wen Tang, Anna H Mooney, Alfonso J Schmidt, Sung H Yang, Geoffrey M Williams, Margaret A Brimble, Matheswaran Kandasamy, Andrew J Marshall, Kate Clarke, Gavin F Painter, Ian F Hermans, Robert Weinkove   +15 more
doaj   +1 more source

Continued control of pneumococcal disease in the UK - the impact of vaccination

, 2011
Streptococcus pneumoniae, also known as the pneumococcus, is an important cause of morbidity and mortality in the developed and developing world. Pneumococcal conjugate vaccines were first introduced for routine use in the USA in 2000, although the seven-
Gladstone, R.A., Jefferies, J.M., Gladstone, R.A, S. N. Faust, Faust, S.N, Faust, S.N ., R. A. Gladstone, Clarke, S.C., J. M. Jefferies, Jefferies, J.M, Clarke, S.C, S. C. Clarke   +11 more
core   +1 more source

7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement? [PDF]

, 2011
BACKGROUND: The UK introduced the 7-valent pneumococcal conjugate vaccine (PCV7) into the national vaccination program in September 2006. Previous modelling assumed that the likely impact of PCV7 on invasive pneumococcal disease (IPD) would be similar to
Nigel Gay, Andrews, Nick, George, Robert, Robert George, Gay Nigel, Miller, Elizabeth, George Robert, Pauline A Waight, Miller Elizabeth, Yoon Hong Choi, N. Gay, Choi, Yoon Hong, Pauline A. Waight, Andrews Nick, R. George, Nick Andrews, Waight Pauline A., Jit, Mark, Gay, Nigel, Jit Mark, Y.H. Choi, Choi Yoon Hong, Elizabeth Miller, M. Jit, P.A. Waight, Melegaro, Alessia, E. Miller, Mark Jit, N. Andrews, Waight, Pauline A, Melegaro Alessia, Alessia Melegaro   +31 more
core   +1 more source

Evolution of conjugate vaccines

Expert Review of Vaccines, 2002
Conjugate vaccines--bacterial polysaccharides conjugated to proteins to improve their immunizing properties--have been a success story since their introduction less than 20 years ago. The Haemophilus influenzae type b conjugate vaccine has nearly eliminated invasive Haemophilus influenzae type b disease in large parts of the world.
P Helena, Mäkelä, Helena, Käyhty
openaire   +2 more sources

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Prospecting the protein design landscape

FEBS Letters, EarlyView.
This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona, Katharina T. Stonig, Jens Meiler, Clara T. Schoeder, Monica L. Fernández‐Quintero   +4 more
wiley   +1 more source